IPdR: a novel oral radiosensitizer

Bibliography

• KINSELLA TJ: An approach to the radiosensitization of human tumors. Cancer J. Sci. Am. (1996) 2:184-193.
   PubMedGoogle Scholar
• MCGINN CJ, SHEWACH DS, LAWRENCE TS: Radiosensitizing nucleosides. J. Natl. Cancer Inst. (1996) 88:1193-1203.
   PubMed Web of Science ®Google Scholar
• MILLER EM, FOWLER JF, KINSELLA TJ: Linear-quadratic analysis of radiosensitization by halogenated pyrimidines. I. Radiosensitization of human colon cancer cells by iododeoxyuridine. Radiat. Res. (1992) 131:81-89.
   PubMed Web of Science ®Google Scholar
• LAWRENCE TS, DAVIS MA, MAYBAUM J, STETSON PL, ENSMINGER WD: The dependence of halogenated pyrimidine incorporation and radiosensitization on the duration of drug exposure. Int. J. Radiat. Oncol. Biol. Phys. (1990) 18:1393-1398.
   PubMed Web of Science ®Google Scholar
• KINSELLA TJ, DOBSON PP, MITCHELL JB, FORNACE AJ: Enhancement of X-ray induced DNA damage by pretreatment with halogenated pyrimidine analogs. Int. J. Radiat. Oncol. Biol. Phys. (1987) 13:733-739.
   PubMed Web of Science ®Google Scholar
• FORNACE AJ, DOBSON PP, KINSELLA TJ: Enhancement of radiation damage in cellular DNA following unifilar substitution with iododeoxyuridine. Int. J. Radiat. Oncol. Biol. Phys. (1990) 18:873-878.
   PubMed Web of Science ®Google Scholar
• LAWRENCE TS, DAVIS MA, MAYBAUM J, STETSON PL, ENSMINGER WD: The effect of single versus double stranded substitution on halogenated pyrimidine-induced radiosensitization and DNA strand breakage in human tumor cells. Radiat. Res. (1991) 123:192-198.
   Web of Science ®Google Scholar
• WANG Y, ILIAKIS G: Effects of 5′-iododeoxyuridine on the repair of radiation induced potentially lethal damage, interphase chromatin breaks, and DNA double strand breaks in Chinese hamster ovary cells. Int. J. Radiat. Oncol. Biol. Phys. (1992) 23:353-360.
   PubMed Web of Science ®Google Scholar
• CHANG AI, COLLINS JM, SPETH PAJ et al.: A Phase I study of intra-arterial iododeoxyuridine in patients with colorectal liver metastases. J. Clin. Oncol. (1989) 6:718-724.
   Google Scholar
• KNOL J, WALKER S, ROBERTSON J et al.: Incorporation of 5-bromo-2′-deoxyuridine into colorectal liver metastases and liver in patient receiving a 7-day hepatic arterial infusion. Cancer Res. (1995) 55:3687-3691.
   PubMed Web of Science ®Google Scholar
• SPETH PAJ, KINSELLA TJ, BELANGER K et al.: Fluorodeoxyuridine modulation of the incorporation of iododeoxyuridine into DNA of granulocytes: a Phase I and clinical pharmacological study. Cancer Res. (1988) 48:2933-2937.
   PubMed Web of Science ®Google Scholar
• MCGINN CJ, KUNUGI KA, TUTSCH KD et al.: Leucovorin modulation of iododeoxyuridine radiosensitization: a Phase I study. Clin. Cancer Res. (1996) 2:1299-1305.
   PubMed Web of Science ®Google Scholar
• KINSELLA TJ, KUNUGI KA, VIELHUBER KA, FOWLER J, FITZSIMMONS M, COLLINS JM: Preclinical evaluation of 5-iodo-2-pyrimidinone-2′-deoxyribose (IPdR) as a prodrug for IUdR-mediated tumor radiosensitization in mouse and human tissues. Clin. Cancer Res. (1998) 4:99-109.
   PubMed Web of Science ®Google Scholar
• KINSELLA TJ, VIELHUBER KA, KUNUGI KA, SCHUPP J, DAVIS TW, SANDS H: Pre-clinical toxicity and efficacy study of a 14-day schedule of oral 5-iodo-2-pyrimidinone-2′-deoxyribose (IPdR) as a prodrug for IUdR-radiosensitization in U251 human glioblastoma xenografts. Clin. Cancer Res. (2000) 6:1468-1475.
   PubMed Web of Science ®Google Scholar
• SEO Y, YAN T, SCHUPP J, RADIVOYEVITCH T, KINSELLA T: Schedule-dependent drug effects of oral 5-iodo-2-pyrimidinone-2′-deoxyribose as a in vivo radiosensitizer in U251 human glioblastoma xenografts. Clin. Cancer Res. (2005) 11:7499-7507.
   PubMed Web of Science ®Google Scholar
• EFANGE SMN, ALESSI EM, SHIH HC, CHENG Y-C, BARDOS TJ: Synthesis and biological activities of 2-pyrimidinone nucleosides. 2. 5-Halo-2-pyrimidinone-2′-deoxyribonucleosides. J. Med. Chem. (1985) 28:904-910.
   PubMed Web of Science ®Google Scholar
• LEWANDOWSKI GA, GRILL SP, FISHER MH et al.: Anti-herpes simplex virus activity of 5-substituted 2-pyrimidinone nucleosides. Antimicrob. Agents Chemother. (1989) 33:340-344.
   PubMed Web of Science ®Google Scholar
• LEWANDOWSKI GA, CHENG Y-C: Mechanism and mode of action of 5-iodo-2-pyrimidinone 2′-deoxyribonucleoside, a potent anti-herpes simplex virus compound, in herpes simplex virus-infected cells. Mol. Pharmacol. (1990) 39:27-33.
   Web of Science ®Google Scholar
• CHANG C-N, DOONG S-L, CHENG Y-C: Conversion of 5-iodo-2-pyrimidinone-2′-deoxyribose to 5-iodo-deoxyuridine by aldehyde oxidase: implications in hepatotropic drug design. Biochem. Pharmacol. (1992) 43:2269-2273.
   PubMed Web of Science ®Google Scholar
• KINSELLA TJ, KUNUGI KA, VIELHUBER KA, MCCULLOCH W, LIU S-H, CHENG Y-C: An in vivo comparison of oral 5-iodo-2′-deoxyuridine and 5-iodo-2-pyrimidinone-2′deoxyribose toxicity, pharmacokinetics, and DNA incorporation in athymic mouse tissues and the human colon cancer xenograft, HCT-116. Cancer Res. (1994) 54:2695-2700.
   PubMed Web of Science ®Google Scholar
• SEO Y, YAN T, SCHUPP JE, COLUSSI V, TAYLOR KL, KINSELLA TJ: Differential radiosensitization in mismatch repair proficient and deficient human colon cancer xenografts with 5-iodo-2-pyrimidinone-2′-deoxyribose. Clin. Cancer Res. (2004) 10:7520-7528.
   PubMed Web of Science ®Google Scholar
• KINSELLA TJ, KINSELLA MT, HONG SW, JOHNSON JP, BURBACK B, TOSCA PJ: Toxicology and pharmacokinetic study of orally administered 5-iodo-2-pyrimidimone-2-deoxyribose (IPdR) x 28 days in Fischer-344 rats: impact on initial Phase I trial design of IpdR-mediated radiosensitization. Cancer Chemother. Pharmacol. (2007) (In Press).
   Google Scholar
• KINSELLA TJ, SCHUPP JE, DAVIS TW et al.: Pre-clinical studies of the systemic toxicity and pharmacokinetics of 5-iodo-2-deoxypyrimidinone-2′-deoxyribose (IPdR) as a radiosensitizing prodrug in two, non-rodent animal species: Implications for Phase I study design. Clin. Cancer Res. (2000) 6:3670-3679.
   PubMed Web of Science ®Google Scholar
• SCHULTZ C, GAFFNEY D, LINDSTROM M, KINSELLA TJ: Iododeoxyuridine radiosensitization of human glioblastoma cells exposed to acute and chronic gamma irradiation: mechanistic implications and clinical relevance. Cancer J. Sci. Am. (1995) 1:151-161.
   PubMedGoogle Scholar
• URTASUN R, KINSELLA T, FARNAM N, DELROWE J, LESTER S, FULTON D: Survival improvement in anaplastic astrocytoma combing external radiation with halogenated pyrimidines: final report of RTOG 86-12, Phase I-II study. Int. J. Radiat. Oncol. Biol. Phys. (1996) 35:1163-1167.
   Web of Science ®Google Scholar
• PRADOS M, SCOTT C, ROTMAN M et al.: Influence of bromodeoxyuridine radiosensitization on malignant glioma patient survival: a retrospective comparison of survival data from the Northern California Oncology group (NCOG) and Radiation Therapy Oncology Group Trials (RTOG) for glioblastoma multiforme and anaplastic astrocytoma. Int. J. Radiat. Oncol. Biol. Phys. (1998) 40:653-659.
   PubMed Web of Science ®Google Scholar
• EISBRUCH A, ROBERTSON JM, JOHNSTON CM et al.: Bromodeoxyuridine alternating with radiation for advanced uterine cervix cancer: a Phase I and drug incorporation study. J. Clin. Oncol. (1999) 17:31-40.
   PubMed Web of Science ®Google Scholar
• EPSTEIN AH, LEBOVICS RS, GOFFMAN T et al.: Treatment of locally advanced cancer of the head and neck with 5′-iododeoxyuridine and hyperfractionated radiation therapy: measurement of cell labeling and thymidine replacement. J. Natl. Cancer Inst. (1994) 86:1775-1780.
   PubMed Web of Science ®Google Scholar
• TOCHNER Z, KINSELLA TJ, ROWLAND J, GLATSTEIN E: Treatment of unresectable sarcomas of adults with hyperfractionated irradiation and iododeoxyuridine. Br. J. Radiol. (1989) 19:107-111.
   Google Scholar
• SONDAK VK, ROBERTSON JM, SUSSMAN JJ, SARAN PA, CHANG AE, LAWRENCE TS: Preoperative idoxuridine and radiation for large soft tissue sarcomas: clinical results with five-year follow-up. Ann. Surg. Oncol. (1998) 5:106-112.
   PubMed Web of Science ®Google Scholar
• LAWRENCE TS, DAVIS MA, MAYBAUM J: Dependence of 5-fluorouracil-mediated radiosensitization on DNA-directed effects. Int. J. Radiat. Oncol. Biol. Phys. (1994) 29(3):519-523.
   PubMed Web of Science ®Google Scholar
• BUCHHOLZ DJ, LEPEK KJ, RICH TA, MURRAY D: 5-Fluorouracil-radiation interactions in human colon adenocarcinoma cells. Int. J. Radiat. Oncol. Biol. Phys. (1995) 32(4):1053-1058.
   PubMed Web of Science ®Google Scholar
• NAKAMOTO S, MITSUHASHI N, TAKAHASHI T, SAKURAI H, NIIBE H: An interaction of cisplatin and radiation in two rat yolk sac tumour cell lines with different radiosensitivities in vitro. Int. J. Radiat. Biol. (1996) 70(6):747-753.
   PubMed Web of Science ®Google Scholar
• DOUPLE EB, RICHMOND RC, O'HARA JA, COUGHLIN CT: Carboplatin as a potentiator of radiation therapy. Cancer Treat. Rev. (1985) 12(Suppl. A):111-124.
   PubMed Web of Science ®Google Scholar
• RAVE-FRÄNK M, SCHMIDBERGER H, CHRISTIANSEN H, BOLL C, LEHMANN J, WEISS E: Comparison of the combined action of oxaliplatin or cisplatin and radiation in cervical and lung cancer cells. Int. J. Radiat. Biol. (2007) 83(1):41-47.
   PubMed Web of Science ®Google Scholar
• GRAU C, OVERGAARD J: Radiosensitizing and cytotoxic properties of mitomycin C in a C3H mouse mammary carcinoma in vivo. Int. J. Radiat. Oncol. Biol. Phys. (1991) 20(2):265-269.
   PubMed Web of Science ®Google Scholar
• TOMA S, PALUMBO R, VINCENTE M et al.: Concomitant doxorubicin (DOXO) by continuous infusion (CI) and radiotherapy (RT) at low doses in locally advanced and/or metastatic soft tissue sarcomas (STS): long-term results of a Phase II study. Proc. Am. Soc. Clin. Oncol. (1995) 14:520 (Abstract).
   Web of Science ®Google Scholar
• VAN RENSBURG CE, SLABBERT JP, BOHM L: Influence of irinotecan and SN-38 on the irradiation response of WHO3 human oesophageal tumour cells under hypoxic conditions. Anticancer Res. (2006) 26(1A):389-393.
   PubMed Web of Science ®Google Scholar
• LAMOND JP, MEHTA MP, BOOTHMAN DA: The potential of topoisomerase I inhibitors in the treatment of CNS malignancies: report of a synergistic effect between topotecan and radiation. J. Neurooncol. (1996) 30(1):1-6.
   PubMed Web of Science ®Google Scholar
• FUKUOKA K, ARIOKA H, IWAMOTO Y et al.: Mechanism of the radiosensitization induced by vinorelbine in human non-small cell lung cancer cells. Lung Cancer (2001) 34(3):451-460.
   PubMed Web of Science ®Google Scholar
• TISHLER RB, SCHIFF PB, GEARD CR, HALL EJ: Taxol: a novel radiation sensitizer. Int J. Radiat. Oncol. Biol. Phys. (1992) 22(3):613-617.
   PubMed Web of Science ®Google Scholar
• MILAS L, FUJII T, HUNTER N et al.: Enhancement of tumor radioresponse in vivo by gemcitabine. Cancer Res. (1999) 59(1):107-114.
   PubMed Web of Science ®Google Scholar
• MOSE S, KARAPETIAN M, JÜLING-POHLIT L et al.: Radiation enhancement of gemcitabine in two human squamous cell carcinoma cell lines. Anticancer Res. (2000) 20(1A):401-405.
   PubMed Web of Science ®Google Scholar
• BLANQUICETT C, SAIF MW, BUCHSBAUM DJ et al.: Antitumor efficacy of capecitabine and celecoxib in irradiated and lead-shielded, contralateral human BxPC-3 pancreatic cancer xenografts: clinical implications of abscopal effects. Clin. Cancer Res. (2005) 11(24 Part 1):8773-8781.
   PubMed Web of Science ®Google Scholar
• SAIF MW, ELOUBEIDI MA, RUSSO S et al.: Phase I study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: expression analysis of genes related to outcome. J. Clin. Oncol. (2005) 23(34):8679-8687.
   PubMed Web of Science ®Google Scholar